High expression of UBE2T predicts poor prognosis and survival in multiple myeloma
Ubiquitin-conjugating enzyme
DOI:
10.1038/s41417-018-0070-x
Publication Date:
2019-01-07T22:46:48Z
AUTHORS (10)
ABSTRACT
Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation plasma cells. Biomarkers play an important role in evaluating the development and prognosis MM. Ubiquitin-conjugating enzyme E2T (UBE2T) served to connect with particular E3 ubiquitin ligase degraded-related substrates, contributing DNA repair Fanconi anemia pathway. Also, numerous evidences reported that UBE2T closely related cell carcinogenesis. However, relationship between MM has not been studied. Here, we integrated eight datasets analyzed expression ISS, 1q21, relapse survival 2684 patients (totally 2893 samples). We found increased deterioration (P = 1.4e-07), especially early stage. IgG serotype 6.9e-05). High associated poor (EFS: P 1.43e-03, OS: 5.47e-05). likely a part division pathway, affecting Therefore, could be considered as alternative biomarker for
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (41)
CITATIONS (32)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....